Thanks for your detailed answers to the complex question.
You lost me at the end when you mentioned the "independent" m6A pathway.
Wouldn't any observed anticancer efficacy at the low to moderate bisantrene doses which will be used be MAINLY due to FTO inhibition rather than to Topo2?
Ann: Updated Strategy and Investor Presentation, page-467
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.055(3.79%) |
Mkt cap ! $237.8M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.33 | $213.7K | 155.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 7167 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |